Introduction
Individuals with a history of cardiovascular disease (CVD) are more likely to experience comorbid depressive symptoms than those without CVD. 1 Conversely, individuals with depression have a 65%
increased risk of developing CVD after controlling for other known risk factors. 2, 3 Depression symptoms have been known to be strong predictors of adverse outcomes, mortality, and hospitalization in patients with CVD. [4] [5] [6] [7] [8] [9] The American Heart Association (AHA) and 2011 Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents reports the prevalence of major depressive disorder (MDD) in patients with CVD is high and emphasizes the need for inclusion of MDD as a Tier II risk factor for CVD. 10 A statement from the AHA Science Advisory and
Coordinating Committee as well as guidelines from Florida Medicaid recommend routine screening and treatment for depression. 11, 12 However, this is rarely done in clinical practice. In a survey by Feinstein et al. 13 on physicians' beliefs, less than 50% of cardiologists reported treating depression and thought it was 'normal' to have depression after CVD events. The European Heart Guidelines (2016) 14 acknowledges that treatment of depression might help improve quality of life and prognosis of CVD. Pharmacological antidepressant treatment options for MDD among patients with CVD can be limited. Monoamine oxidase inhibitors and tricyclic antidepressants are contraindicated due to side effects for patients with CVD with comorbid depression. 11, [15] [16] [17] Therefore, serotonin-norepinephrine reuptake inhibitors (SNRIs) and selective serotonin reuptake inhibitors (SSRIs) are considered to be the main treatment options for MDD among patients with CVD. 18 Although pharmacotherapy is a first-line treatment option, patients who cannot tolerate or respond to medication might need alternative approaches, which include cognitive behavioural therapy and interpersonal psychotherapy, which have shown modest effects. 19 Despite the increasing awareness of the link between depression and CVD, literature on improving CVD outcomes through the early detection and treatment of depression is lacking. The objective of this real-world study was to assess the association between depression care adequacy and the risk of adverse CVD-related outcomes among patients with MDD and a previous diagnosis of myocardial infarction (MI) or stroke (referred to as the CVD cohort).
Methods

Study design
This study employed a retrospective cohort design to compare adverse cardiovascular outcomes in newly diagnosed MI/stroke patients receiving adequate vs. inadequate depression care.
Data source
The study was conducted using Truven Health MarketScan Research Database records from 1 January 2010 to 31 December 2015. The database contained claims from more than 300 contributing employers and 25 contributing health plans across all regions of the United States. This study used a 25% random sample of MI/stroke patients from the Truven Commercial Claims and Encounters, Medicaid Supplemental, and Medicare Supplemental and Coordination of Benefits databases, which included information on enrolment history, patient demographic characteristics (e.g. date of birth, region, gender), claims for medical and pharmacy services, and complete payment information. The databases were de-identified and complied with the Health Insurance Portability and Accountability Act of 1996 to preserve patient anonymity and confidentiality. As the data do not include any patient identifiable information, no individual patient consent, or institutional review board approval was required for this study.
Study population
The study population consisted of newly diagnosed patients with MDD who were first treated for MDD following an initial new diagnosis of MI/ stroke. Patients were identified as having MDD based on an International Classification of Diseases, Ninth Revision (ICD-9) code of 296.2 (MDD single episode), 296.3 (MDD recurrent episode), 300.4 (dysthymic disorder), 311 (Depressive disorder, no elsewhere classified). 20 MDD drugs included major drug classes SSRIs and SNRIs (citalopram, duloxetine, desvenlafaxine, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, and venlafaxine). The date of the first MI/stroke diagnosis was defined as the CVD index date. The 12-month period prior to the CVD index date was defined as the baseline period for identifying patient demographics and clinical comorbidities. The 12-month baseline period was mainly used to exclude depression or antidepression medication usage. In addition, this was done to ensure consistency of length of baseline period for assessing comorbidity burden across all study patients. 21 Following the CVD index date, the date of the first diagnosis of MDD was defined as the MDD index date. The 3-month period following the MDD index date was defined as the profiling period to evaluate the adequacy of depression care received. The period following the profiling period until the end of data capturing was defined as the follow-up period for identification of the adverse CVD outcomes ( Figure 1) . The study population was required to meet the following inclusion criteria:
• Continuous medical enrollment for at least 12 months prior to the CVD index date.
• Continuous medical enrollment for at least 6 months during the follow-up period.
• > _18 years of age at the CVD index date.
• No CVD or MDD diagnosis during the baseline period.
• No use of antidepressant medication during the baseline period.
• No diagnosis of schizophrenia or bipolar disorder at any point during the study period.
Criteria for identifying adequacy of depression care
Depression care adequacy was measured during the 3-month profiling period using antidepressant dosage and duration adequacy criteria. 22 Patients who were adherent to both criteria, defined as follows, were considered to be adequately treated for depression:
• Antidepressant dosage adequacy was defined as a dichotomous variable.
A fluoxetine-equivalent dose of > _20 mg/day for non-elderly patients (aged <65 years) or > _10 mg/day for elderly patients (aged > _65 years) was considered adequate. 23 An average daily dose per patient was calculated by multiplying the drug strength (mg) by the quantity of drug dispensed and dividing the product by the number of days supply. This average daily dose was converted to a fluoxetine-equivalent dose by multiplying it by its fluoxetine dosage equivalent. The average fluoxetine-equivalent dose per day for each patient during the 3-month profiling period was then calculated by summing the average • Antidepressant duration adequacy was defined as the period of time that a patient possessed antidepressant medication. Antidepressant duration was assessed by computing the proportion of days covered (PDC), defined as the number of days between the first prescription fill date and the medication end date, when the patient was actually in possession of a drug. The PDC measure accounts for both gaps in antidepressant therapy (i.e. days when a patient had no possession of a drug) and early prescription refills. A PDC > _80% during the profiling period was considered representative of an adequate treatment duration. 22 
Outcome measures
CVD outcomes considered in this study included MI, stroke, congestive heart failure (CHF), and angina. These outcomes were identified from the end of the profiling period to 31 December 2015, or until death, whichever occurred first. Patients were considered as having any of these CVD outcomes based on a primary or secondary ICD-9-CM and ICD-10-CM diagnosis for the event. A composite CVD outcome combining MI, stroke, CHF, and angina was considered the primary outcome. If a patient encountered multiple adverse CVD events, the occurrence of the first event was considered for the composite outcome measure.
Statistical analysis
Descriptive statistics were reported for the demographic and clinical characteristics of the study population as frequencies and percentages for categorical variables and means with standad deviations for continuous variables. It was anticipated that there would be baseline differences between the patients receiving adequate and inadequate depression care.
To adjust for these differences, a multivariable logistic regression model was used to generate a propensity score as the predicted probability of receiving adequate depression care. Baseline demographics and clinical comorbidities were used as predictors to generate the propensity of receiving adequate depression care. The variables used in the propensity score model included age, sex, region of the country, health insurance plan, Charlson comorbidity index, baseline resource use (pre-index ER, office, and hospital visits), CVD medications used from CVD index date until the end of the profiling period (anti-hyperlipidaemics, anti-hypertensives, anti-coagulants, anti-diabetics). The variables for the propensity score model used a non-parsimonious approach (which is routine) and not necessarily based on statistical significance. All further analysis included this propensity score as a covariate to control for baseline group differences. The time to each outcome was compared between adequately and inadequately treated depression patients using Kaplan-Meier survival curves. Differences between groups in terms of time to the adverse CVD outcomes were assessed using log-rank tests. Cox proportional hazards regression adjusting for the propensity score were used to estimate the hazard ratios (HRs) associated with each CVD outcome. The violation of the assumption of proportional hazards was tested for the outcome measure in each Cox model. Sensitivity analyses were run to test whether the results from the Cox models were different for MI and stroke patients, as well as patients classified as inadequately treated for depression based on the dosage vs. the duration adequacy criteria using tests for interaction. All analyses were conducted using SAS 9.4 (SAS Institute Inc., Cary, NC, USA).
Results
Cohort selection and characteristics
A total of 6763 patients with a new diagnosis of MDD following an initial new diagnosis of MI/stroke were identified. Of these, 1568 patients who were treated for depression during the 3-month profiling period post-MDD index date formed the analytic cohort. In the analytic cohort, 298 (19.01%) patients were identified based on an initial MI diagnosis while 1270 (80.99%) had an index diagnosis of stroke. A total of 937 patients (59.76%) were categorized as receiving inadequate antidepressant treatment. Of these 937 patients, 130 (13.87%) were considered inadequately treated per the dosage adequacy criterion, and 867 (92.52%) were inadequately treated per the duration adequacy criterion (Figure 2) . The study population was primarily female (53.30%) with a mean age of 66.30 years. Patients who received inadequate depression care over follow-up had a significantly greater number of hospitalizations and higher comorbidity 
burden at baseline. The mean follow-up time for the study sample was 2 years ( Table 1) .
Propensity score model to adjust for baseline differences
In order to account for baseline differences between patients with CVD receiving adequate vs. inadequate depression care, all subsequent analyses adjusted for the propensity of receiving adequate depression care. The model discrimination index (c-statistic) for the multivariable logistic regression (i.e. propensity model) to estimate the predicted probability of receiving adequate antidepressant treatment was 0.78.
Unadjusted comparison of adverse cardiovascular disease outcomes
A descriptive comparsion of adverse CVD outcomes over the follow-up revealed that significantly higher proportions of inadequately treated patients with MDD experienced the composite outcome (55.50% vs. 48.65%, P = 0.01), CHF (25.51% vs. 20 .13%, P = 0.01), and angina (6.62% vs. 3 .80%, P = 0.02) when compared with patients receiving adequate antidepressant treatment. There were no significant differences between the groups in terms of MI (4.70% vs. 3 .17%, P = 0.13) and stroke (41.30% vs. 36.45%, P = 0.05). Detailed results for the rate of occurrence of adverse CVD outcomes over the follow-up have been presented in Table 2 .
The Kaplan-Meier curves showing differences in the time to occurrence of adverse CVD outcomes are presented in Figure 3 . The differences between the curves for the composite outcome, stroke, angina, and CHF are significant as indicated by the log-rank test (P < 0.05). This indicates that the time to occurrence of these CVD outcomes was shorter among patients receiving inadequate depression care relative to those receiving adequate treatment. The log-rank tests for MI had the same trend but was not statistically significant.
Adjusted comparison of adverse cardiovascular disease outcomes
The adjusted Cox proportional hazard models assessed the relative burden of inadequate vs. adequate antidepressant care for adverse CVD outcomes ( Table 3) . The proportional hazards assumption was met for all outcome measures. Adjusted Cox proportional hazards models showed that depression care inadequacy was associated with a higher risk of the composite CVD outcome [HR 1.20 , 95% confidence interval (CI) 1.04-1.39; P = 0.02], stroke (HR 1.20, 95% CI 1.02-1.42; P = 0.03), and angina (HR 1.95, 95% CI 1.21-3.16; P = 0.01) compared with patients receiving adequate depression care. Risks of MI (HR 1.37, 95% CI 0.80-2.33; P = 0.25) and CHF (HR 1.14, 95% CI 0.91-1.42; P = 0.25) were numerically higher among patients receiving inadequate depression care but were not significantly different between the two groups.
Although Truven Health Marketscan data do not capture death information (other than inpatient mortality), inpatient mortality (identified by discharge status code = 20), was used to ensure that survivor bias did not drive the results (i.e. higher mortality in the adequate MDD care group did not result in the lower rate of subsequent CVD events). A total of 29 cases of inpatient mortality (8 patients in the adequate MDD care group and 21 in the inadequate MDD care group; P-value = 0.16) were identified. Results from the Cox model suggested a higher risk of inpatient mortality associated with the inadequate MDD care group (HR 1.42, 95% CI 0.59-3.41; P = 0.44) but this HR was not statistically significant. Sensitivity analysis using an interaction terms suggested that the adjusted comparison results did 
not differ for MI and stroke patients (P interaction = 0.07). Additionally, the results did not differ between patients who were categorized as receiving inadequate depression care based on the dosage vs. duration adequacy criteria (P interaction = 0.52).
Discussion
The current study revealed that inadequacy of depression treatment was associated with significantly increased risk of CVD events. All analyses controlled for the propensity of receiving adequate depression care to adjust for group differences in baseline demographic and clinical characteristics.
Specifically, the results of the Cox proportional hazards models suggest that inadequate antidepressant treatment was numerically associated with a greater risk of adverse CVD outcomes. The risk of experiencing the composite CVD outcome, stroke, and angina was significantly greater among patients receiving inadequate depression care. This study help quantify the burden of inadequate antidepressant treatment among patients with CVD. Platelet aggregation plays a very important role as a precursor for adverse CVD outcomes. If not treated, this aggregation can eventually lead to the formation of a thrombus, which puts the patient at an increased risk for many CV related outcomes including stroke, MI, and angina. 24 Depression is linked to disturbances in inflammation, immunity, cognition, and perception, which may worsen CVD symptoms or the patient's ability to communicate or care for their own condition. 25 Patients who are depressed have been shown to have an enhanced thrombogenic response post-MI, and therefore, have a greater chance of experiencing a CV event compared with their non-depressed counterparts. Studies have shown that modifications in platelet function in patients with MDD are in part due to the link between platelet aggregation and serotonergic processes in the brain. Serotonin acts upon the thrombogenic pathway by acting as a platelet de-aggregate, however, in depressed patients this response is often limited due to the decline of this essential mood stabilizing agent. 26 Drugs such as SSRI's are unique in their ability to block the reuptake of serotonin, thus causing an increase of the mood stabilizing neurotransmitter in the synaptic cleft. The ability that SSRIs have in decreasing platelet aggregation has been shown to have cardioprotective effects in patients post-MI. 26 This protection can be characterized by two distinct pathophysiological mechanisms: changes in sympathetic-parasympathetic balance and decrease in heart rate variability. 26 Studies have shown that SSRIs such as sertraline can recover heart rate variability in depressed patients with prior-MI. 26 Therefore, adequate depression care characterized by appropriate dosage and duration of treatment may have resulted in a lower risk of adverse CVD outcomes in the current study. Additionally, the current study found that the prevalence of inadequate depression care was as high as 60% based on two treatment adequency definition criteria (antidepressant dosage and duration adequacy) outlined in the APA and VHA guidelines. [27] [28] [29] Consistent with previous literature, 27,30 this study found that about 91% of patients were adequately treated based on the dosage adequacy criterion and 45% of the patients were adequately treated based on the duration adequacy criterion. 31 The findings suggest that despite established guidelines mapping the appropriate care of patients with post-stroke and post-MDD, clinicians often fail to implement current standards of care. The field would benefit from research investigating the barriers and solutions for administering guideline-driven treatment in this patient population. This study has several strengths. First, real-world claims data was used from patients in actual clinical practice settings, making the results generalizable to a population of commercially insured adults in the United States. The measures used to assess antidepressant treatment adequacy were based on clinical guideline benchmarks that have been adopted by previous studies and must be implemented by future studies as well to better assess their reliability and validity. 27 Performance testing of these measures is also important for agencies such as the Health Plan Employer Data and Information System (HEDIS) and the Agency for Healthcare Research and Quality (AHRQ) as they develop and refine mental health-specific quality measures for better allocation of health care resources. Second, controlling by the propensity score in all multivariable analyses helped account for baseline differences between the study cohorts and reduced the chances of selection bias. Third, sensitivity analyses confirmed that the results did not differ based on whether patients with CVD had an initial MI or stroke diagnosis or whether they were categorized as inadequately treated based on the antidepressant dosage or duration adequacy criteria. Last, we compared newly diagnosed post-CVD depression patients receiving adequate vs. inadequate depression care in terms of a broad set of clinical outcome measures, which enhanced the clinical relevance of the study results. The results of the current study must be interpreted in the light of certain limitations. First, the current study was not a randomized comparison and as such any causal inferences between depression care adequacy and risk of CVD outcomes cannot be made. Although propensity score adjustment was used to account for known baseline confounders between the two groups, the models cannot take into account unmeasured confounders. Second, the study did not control for frailty although this could be a predictor of adverse CVD outcomes. This information was not available in the claims data but could be captured in studies that employ a review of patient charts.
However, total comorbidity burden for each patient was accounted for by including the CCI score as a covariate in all multivariable analysis. Third, availability of clinically detailed information such as change in depression symptomology over the profiling period could help establish the criterion validity of the measures used to assess depression care adequacy, but this information is not captured in administrative claims data. Fourth, administrative claims data do not capture information on depression severity nor the nonpharmacological treatment used. The severity of depression symptoms may have impacted the manner and extent to which patients 
were treated. Fifth, the dataset did not include all-cause mortality related information. The data does capture inpatient mortality. A sensitivity analysis conducted using inpatient mortality as an outcome showed a higher albeit statistically nonsignificant risk among patients receiving inadequate MDD care. This suggested that the study results may not be driven by survivor bias (i.e. higher mortality in the adequate MDD care patients driving the lower subsequent rate of CVD events). Sixth, the use of administrative dataset to identify MDD may potentially result in misclassification. However, we do not anticipate that this would differentially affect the two groups (based on adequacy of MDD treatment). Lastly, while we do recognize that the results of the composite CVD endpoint may be driven by one or more individual CVD endpoint, to address this each the risk of each adverse CVD event (which formed the composite outcome) was also modelled separately.
The current study shows that among patients with CVD, the prevalence of inadequate depression care is high and such inadequate care is associated with significantly greater risk of adverse CVD events. It is, therefore, key for clinicians and health care decision makers to consider these findings when screening for and treating comorbid depression in this high-risk patient population. Further research that takes disease-related, patient-related, and physician-related barriers into consideration is warranted to align current clinical practice with the ideal standards for evidence-based practice. Future studies must also assess the economic burden of inadequate antidepressant treatment including outcomes such as health care resource use and cost of patient care. Obtained from Cox proportional hazards models adjusted for the propensity of receiving adequate depression care.
